ABBOTT LABORATORIES Funds and ETFs Abbott Laboratories
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.8 USD | +0.03% |
|
-0.82% | -4.82% |
| 05-09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
| 05-08 | Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing | MT |
ETFs positioned on Abbott Laboratories
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.55% | 9 M€ | +8.59% | ||
| 0.55% | 5 M€ | -.--% | - | |
| 0.52% | 2,517 M€ | +12.10% | - | |
| 0.50% | 1,006 M€ | -.--% | - | |
| 0.50% | 414 M€ | +11.88% | - | |
| 0.49% | 7 M€ | +6.22% | - | |
| 0.49% | 57 M€ | +20.49% | - | |
| 0.49% | 205 M€ | -.--% | ||
| 0.48% | 322 M€ | +13.88% | - | |
| 0.48% | 29 M€ | -.--% | - | |
| 0.48% | 1 M€ | -.--% | ||
| 0.47% | 7 M€ | +0.11% | - | |
| 0.45% | 34 M€ | +11.62% | - | |
| 0.41% | 727 M€ | +8.19% | ||
| 0.40% | 25 M€ | +3.50% | - | |
| 0.40% | 283 M€ | +19.39% | ||
| 0.39% | 14 M€ | +16.19% | - | |
| 0.39% | 284 M€ | -.--% | ||
| 0.38% | 234 M€ | +2.60% | - | |
| 0.38% | 23 M€ | -.--% | - | |
| 0.38% | 786 M€ | -.--% | ||
| 0.37% | 50 M€ | +9.46% | ||
| 0.36% | 206 M€ | -.--% | ||
| 0.33% | 1 M€ | +3.03% | - | |
| 0.32% | 607 M€ | +0.05% | - |
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Calendar
17/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104.8
USD
Average target price
126.1
USD
Spread / Average Target
+20.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.82% | 182B | |
| +1.38% | 111B | |
| -2.82% | 68.48B | |
| +0.69% | 49.69B | |
| +8.54% | 44.46B | |
| +2.33% | 40.67B | |
| +20.50% | 31.22B | |
| +1.72% | 26.09B | |
| +15.30% | 25.32B | |
| -1.73% | 24.6B |
- Stock Market
- Equities
- ABT Stock
- Funds and ETFs Abbott Laboratories
